nephrocystin-3 Activators
Chemical activators of nephrocystin-3 can leverage the intracellular signaling mechanisms to enhance its function within the cellular pathways it is involved in. Forskolin, by activating adenylate cyclase, leads to an increase in cyclic AMP (cAMP) levels within the cell, which in turn activates protein kinase A (PKA). Activated PKA can then phosphorylate nephrocystin-3 or proteins in its associated pathways, thereby functionally activating nephrocystin-3. Similarly, isoproterenol, a beta-adrenergic agonist, elevates cAMP levels through G protein-coupled receptor signaling, resulting in PKA activation. The phosphorylation cascade that follows can have a direct impact on nephrocystin-3, promoting its activation. IBMX acts as a non-selective inhibitor of phosphodiesterases, preventing the degradation of cAMP, and the resulting elevation of cAMP again leads to PKA activation with downstream effects on nephrocystin-3 activation.
Continuing with this theme, Anagrelide and Rolipram both inhibit different isoforms of phosphodiesterase, leading to increased cAMP and subsequent activation of PKA, which can phosphorylate and activate nephrocystin-3. Histamine interacts with H2 receptors to raise cAMP levels, thereby activating PKA which then targets proteins within the nephrocystin-3 pathway. Terbutaline and epinephrine, acting through beta-adrenergic receptors, and dopamine, through D1-like receptors, all increase cAMP in the cell, catalyzing a similar PKA-mediated activation process for nephrocystin-3. Cholera toxin permanently activates the Gs alpha protein, which leads to a sustained increase in cAMP levels and continuous activation of PKA; this could lead to a prolonged activation of nephrocystin-3. Zaprinast selectively inhibits phosphodiesterase V, causing an increase in cAMP which then activates PKA, potentially leading to the activation of nephrocystin-3. Collectively, these chemical activators can enhance the functional state of nephrocystin-3 by harnessing the cAMP-PKA signaling axis and its role in protein phosphorylation within the cell.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates adenylate cyclase, increasing cAMP levels, which can lead to the activation of PKA. PKA can phosphorylate proteins in the pathway that includes nephrocystin-3, potentially enhancing its function in signaling or ciliary mechanisms. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Isoproterenol is a beta-adrenergic agonist that can increase cAMP levels through G protein-coupled receptor signaling, leading to activation of PKA. PKA then could phosphorylate components in the pathway involving nephrocystin-3, facilitating its activation. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a non-selective inhibitor of phosphodiesterases which increases cAMP by preventing its degradation. Elevated cAMP activates PKA, which may then phosphorylate and activate proteins in pathways that include nephrocystin-3. | ||||||
PGE2 | 363-24-6 | sc-201225 sc-201225C sc-201225A sc-201225B | 1 mg 5 mg 10 mg 50 mg | $57.00 $159.00 $275.00 $678.00 | 37 | |
Prostaglandin E2 (PGE2) interacts with its G protein-coupled EP receptors to elevate cAMP, again leading to PKA activation. PKA can phosphorylate proteins in the pathway with nephrocystin-3, possibly activating its function. | ||||||
Anagrelide | 68475-42-3 | sc-491875 | 25 mg | $150.00 | ||
Anagrelide increases cAMP by inhibiting phosphodiesterase III. The subsequent activation of PKA can lead to phosphorylation of proteins within nephrocystin-3's pathway, thus potentially enhancing its activation. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram is a selective inhibitor of phosphodiesterase IV, leading to increased cAMP and activation of PKA. PKA may phosphorylate and activate nephrocystin-3 directly or proteins associated with its pathway. | ||||||
Histamine, free base | 51-45-6 | sc-204000 sc-204000A sc-204000B | 1 g 5 g 25 g | $94.00 $283.00 $988.00 | 7 | |
Histamine, through H2 receptor activation, can increase cAMP in the cell, which activates PKA. PKA could phosphorylate proteins within the nephrocystin-3 pathway, leading to its functional activation. | ||||||
Dopamine | 51-61-6 | sc-507336 | 1 g | $290.00 | ||
Also called Dopamine, this compound can bind to D1-like receptors, which activates adenylate cyclase to increase cAMP and activate PKA. PKA, in turn, could phosphorylate and activate nephrocystin-3 or its pathway proteins. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
Zaprinast is a selective inhibitor of phosphodiesterase V, which increases cAMP and thereby activates PKA. PKA could then phosphorylate and functionally activate nephrocystin-3 or related pathway proteins. | ||||||
(−)-Epinephrine | 51-43-4 | sc-205674 sc-205674A sc-205674B sc-205674C sc-205674D | 1 g 5 g 10 g 100 g 1 kg | $41.00 $104.00 $201.00 $1774.00 $16500.00 | ||
Epinephrine, through beta-adrenergic receptors, increases cAMP in the cell, leading to PKA activation. PKA may then phosphorylate proteins in the pathway that includes nephrocystin-3, possibly leading to its activation. | ||||||